PMID- 9116297
OWN - NLM
STAT- MEDLINE
DCOM- 19970422
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 89
IP  - 7
DP  - 1997 Apr 1
TI  - 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia 
      characterized by extensive nodal involvement and inferior prognosis.
PG  - 2516-22
AB  - Deletions of the long arm of chromosome 11 (11q) are one of the most frequent 
      structural chromosome aberrations in various types of lymphoproliferative 
      disorders. However, in most conventional chromosome banding studies of B-cell 
      chronic lymphocytic leukemia (B-CLL), 11q deletions were not identified as a 
      frequent aberration. The objective of this study was to analyze the frequency and 
      clinical impact of 11q deletions in B-CLL by interphase cytogenetics using 
      fluorescence in situ hybridization (FISH). Mononuclear cells from 214 patients 
      with B-CLL were studied by FISH using the yeast artificial chromosome (YAC) clone 
      755b11 from chromosome region 11q22.3-q23.1; we previously showed that this clone 
      was contained within a 2- to 3-Mb sized segment of 11q commonly deleted in 
      lymphoproliferative disorders. Forty-three of the 214 (20%) tumors exhibited 11q 
      deletions; 11q deletions were the second most frequent chromosome aberration 
      following 13q14 (RB1 and/or D13S25) deletions (45%); they were more frequent than 
      trisomy 12 (15%) or deletion of 17p (TP53 gene) (10%). Patients with 11q 
      deletions were younger (P = .01) and had more advanced clinical stages (P = .01). 
      11q deletions were associated with extensive peripheral, abdominal, and 
      mediastinal lymphadenopathy (P < .001). Patients with 11q deletions had a more 
      rapid disease progression as shown by a shorter treatment-free interval (9 months 
      v 43 months; P < .001). The prognostic effect of 11q deletion on survival 
      strongly depended on the age: in patients less than 55 years old, the median 
      survival time was significantly shorter in the deletion group (64 months v 209 
      months; P < .001), whereas in patients > or = 55 years old there was no 
      significant difference (94 months v 111 months; P = .82). 11q deletions identify 
      a new clinical subset of B-CLL characterized by extensive lymph node involvement. 
      In younger B-CLL patients, this aberration is an important predictor of survival.
FAU - Dohner, H
AU  - Dohner H
AD  - Medizinische Klinik and Poliklinik V, Universitat Heidelberg, Germany.
FAU - Stilgenbauer, S
AU  - Stilgenbauer S
FAU - James, M R
AU  - James MR
FAU - Benner, A
AU  - Benner A
FAU - Weilguni, T
AU  - Weilguni T
FAU - Bentz, M
AU  - Bentz M
FAU - Fischer, K
AU  - Fischer K
FAU - Hunstein, W
AU  - Hunstein W
FAU - Lichter, P
AU  - Lichter P
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Aberrations
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 11/*ultrastructure
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, 
      B-Cell/*classification/genetics/mortality/pathology
MH  - Lymph Nodes/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - S0006-4971(20)59061-7 [pii]
PST - ppublish
SO  - Blood. 1997 Apr 1;89(7):2516-22.